{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:05:30Z","timestamp":1773968730325,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273429"],"award-info":[{"award-number":["82273429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303203"],"award-info":[{"award-number":["82303203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.acra.2025.12.037","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:28:15Z","timestamp":1768249695000},"page":"835-844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of RALOX-HAIC-based Combination Therapy for Unresectable Hepatocellular Carcinoma with Radiomics-Powered Prediction"],"prefix":"10.1016","volume":"33","author":[{"given":"Peilin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanzhou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengguang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengya","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangfeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinzhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangda","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acra.2025.12.037_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.acra.2025.12.037_bib2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","article-title":"World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma","volume":"62","author":"de Martel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.acra.2025.12.037_bib3","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.acra.2025.12.037_bib4","first-page":"443","article-title":"Cancer statistics for adolescents and young adults, 2020","volume":"70","author":"Miller","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.acra.2025.12.037_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acra.2025.12.037_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.acra.2025.12.037_bib7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acra.2025.12.037_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.12.037_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib11","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib12","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000343875","article-title":"JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan","volume":"3","author":"Kudo","year":"2015","journal-title":"Liver Cancer"},{"key":"10.1016\/j.acra.2025.12.037_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40880-017-0251-2","article-title":"Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study","volume":"36","author":"He","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.acra.2025.12.037_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib16","first-page":"1163","volume":"31","author":"Li","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.acra.2025.12.037_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma","volume":"11","author":"Mei","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.acra.2025.12.037_bib20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000505692","article-title":"Exploratory analysis to identify candidates benefitting from combination therapy of transarterial chemoembolization and sorafenib for first-line treatment of unresectable hepatocellular carcinoma: a multicenter retrospective observational study","volume":"9","author":"Wang","year":"2020","journal-title":"Liver cancer"},{"key":"10.1016\/j.acra.2025.12.037_bib21","first-page":"395","article-title":"FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma","volume":"67","author":"Lyu","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.acra.2025.12.037_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111019","article-title":"Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: a retrospective study","volume":"125","author":"Zang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.acra.2025.12.037_bib23","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1097\/HEP.0000000000001401","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.acra.2025.12.037_bib24","article-title":"Automated ultrasonography of hepatocellular carcinoma using discrete wavelet transform based deep-learning neural network","volume":"101","author":"Se-Yeol","year":"2025","journal-title":"Med Image Anal"},{"key":"10.1016\/j.acra.2025.12.037_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46695-8","article-title":"Wavelet radiomics features from multiphase CT images for screening hepatocellular carcinoma: analysis and comparison","volume":"13","author":"Tang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.acra.2025.12.037_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.613946","article-title":"Development and validation of a contrast-enhanced CT-based radiomics nomogram for prediction of therapeutic efficacy of anti-PD-1 antibodies in advanced HCC patients","volume":"11","author":"Yuan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.acra.2025.12.037_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.12.037_bib28","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.14309\/ajg.0000000000001256","article-title":"Effect of diameter and number of hepatocellular carcinomas on survival after resection, transarterial chemoembolization, and ablation","volume":"116","author":"Kawaguchi","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.acra.2025.12.037_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acra.2025.12.037_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00428-017-2288-7","article-title":"Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics","volume":"472","author":"Hirsch","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.acra.2025.12.037_bib31","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggi","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.acra.2025.12.037_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/07357909909032859","article-title":"5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy","volume":"17","author":"Iyer","year":"1999","journal-title":"Cancer Invest"},{"key":"10.1016\/j.acra.2025.12.037_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.12.037_bib34","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.1996.14.5.1495","article-title":"Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors","volume":"14","author":"Clarke","year":"1996","journal-title":"J Clin Oncol"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225011730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225011730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:21:13Z","timestamp":1773962473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633225011730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1076633225011730"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2025.12.037","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of RALOX-HAIC-based Combination Therapy for Unresectable Hepatocellular Carcinoma with Radiomics-Powered Prediction","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2025.12.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}